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Syk inhibitors in clinical development for
hematological malignancies
Delong Liu1* and Aleksandra Mamorska-Dyga2
Abstract
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in
hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a
key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors.
Several oral Syk inhibitors including fostamatinib (R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and
TAK-659 are being assessed in clinical trials. The second generation compound, entospletinib, showed promising
results in clinical trials against B-cell malignancies, mainly chronic lymphoid leukemia. Syk inhibitors are being
evaluated in combination regimens in multiple malignancies.
Background
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor
protein tyrosine kinase (PTK) which was discovered in
1990 [1]. The full-length syk cDNA was first cloned from
porcine spleen cells in 1991 [2]. The human syk cDNA
contains an open reading frame of 1908 base pairs. The
human syk gene encodes a 635-aa polypeptide with an
estimated molecular weight of 72 kDa [3, 4]. The syk
gene was found to be localized on chromosome 9q22.
Syk is mainly expressed in hematopoietic cells. Syk
belongs to the Src family of non-receptor type PTKs and
is highly homologous to ZAP-70, which is thought to be
the Syk counterpart in T cells [4, 5].
Syk contains two N-terminal SH2 domains and one C-
terminal tyrosine kinase domain. The SH2 domains of
Syk bind to immunoreceptor tyrosine-based activation
motifs (ITAMs), leading to Syk activation. Syk protein
lacks myristoylation site, therefore does not attach
directly to the cell membrane [2, 4, 5].
Syk has an autophosphorylation site at Tyr-518.
Following receptor engagement such as antigen binding
or sIgM ligation in B cells, tyrosine residues are phos-
phorylated by Lyn, another Src-family non-receptor
PTK. The phosphorylation on the tyrosine residues in
Syk creates binding sites for CBL, VAV1, and phospho-
lipase C-gamma, the regulators of B-cell receptor (BCR)
signaling pathways. These lead to an increase in second
messenger IP3 which stimulates calcium ion
mobilization.
Syk functions
Syk was recognized as a critical element in the BCR sig-
naling pathway [6, 7]. Syk is also a key component in
signal transduction from other immune receptors like Fc
receptors and adhesion receptors. Syk along with other
BCR signaling molecules, Bruton tyrosine kinase (BTK),
PI3K delta (PI3Kδ), and tumor necrosis factor (TNF)
superfamily receptors was also found to be involved in
signal transduction independent from the BCR [8–10].
Syk is expressed primarily in hematopoietic cells like B-
cells, monocytes, macrophages, mast cells, and neutro-
phils. Syk was recognized to be a potential target for the
treatment of various hematologic cancers, autoimmune
disorders, and other inflammatory states [11–16]. Under
resting conditions, Syk remains in unphosphorylated
state. Activation of the BCR leads to oligomerization
and phosphorylation of the Igα and ß (immunoreceptor
tyrosine-based activation motifs, ITAMs), the transmem-
brane signaling proteins CD79a and CD79b. The latter
results in activation of the Syk tyrosine kinase, which in
turn initiates downstream signaling through PI3K and
BTK leading to amplification of the original BCR signal.
In animal models Syk was found to be a critical point in
B-cell antibody responses, differentiation into germinal
center or plasma cells and memory B-cells [17–19].
* Correspondence: delong_liu@nymc.edu
1Department of Oncology, The first Affiliated Hospital of Zhengzhou
University, Zhengzhou 450052, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Liu and Mamorska-Dyga Journal of Hematology & Oncology  (2017) 10:145 
DOI 10.1186/s13045-017-0512-1
Syk inhibitors
Several oral Syk inhibitors including fostamatinib (R788),
entospletinib (GS-9973), cerdulatinib (PRT062070), and
TAK-659 are being assessed in clinical trials [9]. Preclinical
studies of a few Syk inhibitors have been reported [20–23].
Fostamatinib
Fostamatinib is the first oral Syk inhibitor (previously
known as R788). It is rapidly metabolized in vivo to
R406 [24, 25]. Fostamatinib can selectively abrogate the
BCR signaling pathway. Fostamatinib has potent anti-
inflammatory effects [18, 26]. It was first demonstrated
to have activities in rheumatoid arthritis and immune
thrombocytopenia [11, 27–31]. In a murine model of
chronic lymphoid leukemia (CLL) fostamatinib was
found to induce an early and transient mobilization of
both normal and malignant B cells, but selectively inhib-
ited the growth of the malignant B-cell population [32].
This effect on mobilization of B cells is similar to that of
BTK inhibitors [10, 33–39].
Fostamatinib was the first clinically available Syk in-
hibitor which was tested in a phase I/II study in patients
with refractory B-cell lymphomas [40]. The dose-
limiting toxicity (DLT) was diarrhea, neutropenia, and
thrombocytopenia. The highest response (n = 6, 55%)
was seen in patients with CLL/SLL (n = 11). The overall
response rate (ORR) among the 23 patients with diffuse
large B-cell lymphoma (DLBCL) in the phase II part was
22%. Among the five responders, there were one
complete response (CR) and four partial responses (PR).
Median progression-free survival (PFS) for the patients
in the phase II group was 4.2 months, and for DLBCL
patients, the median PFS was 2.7 months. This trial
established the phase II dose at 200 mg BID.
Fostamatinib was studied in patients with relapsed or
refractory DLBCL in a phase II, two-arm, randomized,
double-blinded trial at either 100 mg twice a day (BID)
or 200 mg BID. The ORR was the primary endpoint.
Due to limited efficacy at the lower dosage, all subse-
quent patients were treated at 200 mg BID. At the time
of the report [41], 68 patients were treated (47 at
200 mg BID, 21 at 100 mg BID). Of these patients, 58%
were germinal B-cell (GCB) origin, 30% activated B-cell
(ABC) origin. Diarrhea, nausea, and fatigue were the
most common treatment-related adverse events (TEAE).
The ORR was 3%. Patients with the ABC genotype failed
to respond. Off-target effects on VEGFR and other
tyrosine kinases were thought to be responsible for the
most common TEAEs [24, 42].
Entospletinib (GS-9973)
The search for more kinase-selective oral Syk inhibitor
resulted in the discovery of GS-9973, entospletinib [43].
This second generation compound demonstrated favorable
in vitro and in vivo selectivity profile with fewer dose-
limiting adverse effects. Entospletinib in comparison to
fostamatinib revealed increased selectivity for Janus kinase
2 (JAK-2), c-KIT, FMS-like tyrosine kinase 3 (FLT 3), RET,
and VEGFR2 [43].
Preclinical studies in CLL cell lines demonstrated that
inhibition of Syk activity leads to decreased secretion of
CCL3 and CCL4 resulting in cell redistribution. The
disruption of the microenvironment of B-cells and
surrounding stroma by Syk inhibitors mitigates the
chemokine- and integrin-mediated protective effects of
CLL cells [44–46]. Clinically this effect manifests as
lymph node reduction with associated transient marked
lymphocytosis. These effects make entospletinib an ideal
agent for refractory CLL and other B cell non-Hodgkin
lymphomas (NHL) [47, 48].
Entospletinib (GS-9973) was evaluated in a multicen-
ter, phase 2 study on subjects with relapsed or refractory
CLL (n = 41) and non-Hodgkin lymphoma (n = 145)
[47]. Patients received 800 mg entospletinib twice daily.
This report provided results of efficacy in CLL and safety
in all patients (n = 186). The prior treatment for CLL
must have included at least 2 cycles of therapeutic
antibody or cytotoxic therapy. The median progression-
free survival (PFS) for CLL was 13.8 months (95% CI,
7.7 months to not reached). The ORR was 61.0% (95% CI,
44.5–75.8%), with 25 partial responses (PR), 13 patients
with stable disease, and no complete responses (CR).
94.9% of the patients in the CLL cohort achieved reduc-
tion in adenopathy. There were three patients who had
nodal reduction with persistent lymphocytosis. The rate of
serious adverse events (SAEs) was 29%. The most com-
mon TEAEs included dyspnea, pneumonia, febrile neutro-
penia, and pyrexia. The study showed that entospletinib
had clinical activity in subjects with relapsed or refractory
CLL [49]. The toxicity was acceptable in the whole patient
population with CLL and NHL.
In updated report of 69 patients with indolent NHL
(41 follicular lymphoma (FL), 11 lymphoplasmacytoid
lymphoma (LPL), 17 marginal zone lymphoma (MZL)),
entospletinib 800 mg BID was evaluated in a multicenter
phase II study as mentioned above [48]. Median age of
the cohorts was 66 years (range 41–89). The subjects
received a median number of 3 prior treatment regimens
(range 1–14). Entospletinib was generally well tolerated.
The most common TEAEs were fatigue and GI toxic-
ities. Common laboratory abnormalities were elevation
of ALT /AST and bilirubin as well as anemia and neutro-
penia. The ORR was 13.0% (95% CI: 6.1% to 23.3%), with
7 PR, and one CR. The median PFS was 5.5 months
(95% CI: 4.4 to 8.2 months). Therefore, entospletinib
monotherapy 800 mg BID was well tolerated and
showed clinical activity in patients with advanced
indolent NHL. Entospletinib was shown recently in a
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phase II study to have modest activity in 39 patients with
relapsed or refractory mantle cell lymphoma (MCL)
[50]. Further development of entospletinib in NHL will
likely focus on the combination regimens [50].
Recently, the interim results of the entospletinib
monotherapy and in combination with chemotherapy in
patients with AML were presented. In this ongoing
phase 1b/2 study (NCT02343939), entospletinib was well
tolerated [51]. At the time of this report, the study
enrolled 12 patients with a median age of 54 (range, 18–
69) years. Three patients were treated at 200 mg BID,
and six were dosed at 400 mg BID. The most common
non-hematologic AEs included febrile neutropenia, nau-
sea, and diarrhea. Taken all the data together, there was
lack of benefit to escalate dose pass 400 mg BID. There-
fore, 400 mg BID was selected as the recommended
phase 2 dose. Surprisingly, 9/9 patients (100%) treated at
both levels achieved CR. One patient with 11q23-
rearranged AML achieved morphologic and cytogenetic
CR after 14 days on entospletinib monotherapy, indicat-
ing unique sensitivity to the drug in this patient with
poor prognosis [51].
Entospletinib in combination regimens
PI3Kδ inhibitors and BTK inhibitors as well as
immune check point inhibitors are novel agents that
have changed the clinical management of CLL and
NHLs [8, 10, 35, 52–56]. Prolonged administration of
these agents is, however, needed, and resistance is
already emerging in a proportion of patients [57, 58].
Therefore, combination of entospletinib and idelalisib
was evaluated in an attempt to enhance the efficacy
and reduce resistance [59, 60].
An open-label phase II study evaluated the safety and
efficacy of the combination of entospletinib and idelali-
sib [60]. The study included 66 patients in five cohorts
of indolent NHL, CLL, MCL, and DLBCL. The primary
end point was ORR. The patients underwent intra-
patient dose escalation of idelalisib and entospletinib
(from 100 to 150 mg and 200 to 800 mg twice daily,
respectively) every 2 or 4 weeks. After treatment for a
median of 10 weeks, the ORR reached 60% in the CLL
cohort, 36% in follicular lymphoma, and 17% in DLBCL.
The most common AEs were diarrhea, rash, and transa-
minitis, which improved after treatment discontinuation.
However, there were 12 patients who developed pneu-
monitis, 11 of grade 3 or more, resulting in two fatalities.
The study was therefore terminated. Such a severe pro-
inflammatory response was attributed to the unexpected
potent inhibition of the mammalian target of rapamycin
(mTOR) observed with the combination of the two
study drugs. Increased T helper 1 (Th-1) response
mediated by interferon-γ, IL- 6, 7, 8 was reported in
patients with pneumonitis [60].
Events from the idelalisib and entospletinib phase II
study prompt researchers to exert caution in planning
and conducting further trials with Syk inhibitors in
conjunction with other BCR inhibitors or in combin-
ation with chemotherapy (Table 1).
Despite recent advances in molecular diagnosis and
clinical therapy, relapsed and refractory acute lymph-
oid leukemia (R/R ALL) remains a significant chal-
lenge [61–68]. Novel agents are being developed to
improve the outcome of R/R ALL [64, 65, 69–74].
Entospletinib was studied in combination with vincris-
tine and shown to have synergistic activity in vitro in
19 hematological cancer cell lines including lymph-
oma, multiple myeloma, ALL, and AML [75]. The in
vivo efficacy of entospletinib and vincristine as singe
agents and in combination was further evaluated in a
lymphoma xenograft model using the SU-DHL-10 cell
line. The combination of vincristine with entospletinib
showed synergistic activity in ALL in the mouse
model and thus supported the further clinical devel-
opment of entospletinib in combination with vincris-
tine [76]. A phase 1b trial (NCT02404220) is
evaluating entospletinib in combination with chemo-
therapy (vincristine and dexamethasone) for the treat-
ment of R/R Pre B-ALL. In the last update, three
patients have been enrolled [77].
Table 1 Clinical trials of entospletinib
Phase Diseases Interventions NCT ID
2 CLL, MCL, DLBCL, non-FL iNHL, FL Entospletinib monotherapy NCT01799889
1/2 AML Entospletinib monotherapy NCT02343939
2 CLL, MCL, DLBCL, iNHL Entospletinib with idelalisib NCT01796470
1 ALL Entospletinib, vincristine, dexamethasone NCT02404220
2 GVHD Entospletinib, placebo, corticosteroids NCT02701634
1 Entospletinib NCT02521376
1 B-cell malignancies Entospletinib, idelalisib, ONO/GS-4059 NCT02457598
1, 2 NHL Entospletinib, vincristine NCT02568683
AML acute myelogenous leukemia, ALL acute lymphocytic leukemia, CLL chronic lymphocytic leukemia, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma,
GVHD graft versus host disease, MCL mantle cell lymphoma, NHL non-Hodgkin lymphoma, iNHL indolent NHL
Liu and Mamorska-Dyga Journal of Hematology & Oncology  (2017) 10:145 Page 3 of 7
Cerdulatinib (PRT062070)
Cerdulatinib is a dual inhibitor of Syk and JAK 1/3 and
has been shown to have activity against DLBCL in in
vitro studies [78]. Cerdulatinib is an oral kinase inhibitor
against Syk and JAK. It has been shown in vitro to have
specific inhibitory activity against Syk and JAK1/3 in a
subset of B-cell lymphoma cell lines. Cerdulatinib sup-
pressed inflammation and autoantibody generation and
blocked B-cell activation in a rat model and splenomeg-
aly in a mouse model of chronic B-cell antigen receptor
stimulation. In both ABC and GCB lymphoma cell lines,
cerdulatinib induced apoptosis and cell-cycle arrest. Cer-
dulatinib blocked JAK/STAT and BCR signaling in pri-
mary GCB and non-GCB DLBCL tumor cells [79].
Primary CLL cells from patients were treated in vitro
with cerdulatinib alone or in combination with veneto-
clax. Cerdulatinib inhibited BCR- and IL4-induced
downstream signaling in CLL cells and reduced CCL3/
CCL4 production. Cerdulatinib and venetoclax have syn-
ergistic activity in primary CLL cells [80]. Interestingly,
cerdulatinib was shown to be better than ibrutinib in
overcoming the stromal support and blocking prolifera-
tion of ibrutinib-resistant primary CLL cells and of
BTKC481S-transfected/ibrutinib-resistant lymphoma
cells [81]. Phase I/II dose escalation study in CLL/SLL/
NHL is underway (NCT01994382) [78, 82].
TAK-659
Syk directly binds to and activates FMS-like tyrosine
kinase 3 (FLT-3) [17]. Through structure-based drug de-
sign, a novel series of heteroaromatic Syk inhibitors was
screened and optimized, resulting in the discovery of
TAK-659, a dual Syk and FLT3 inhibitor [83]. TAK-659
inhibited the pro-survival, proliferative, chemoresistant,
and activation effects promoted by the microenviron-
ment. Combination of TAK-659 with other BCR inhibi-
tors showed synergistic effect in inducing apoptosis.
Combination of TAK-659 and ibrutinib induced signifi-
cantly higher cytotoxicity toward CLL cells [84].
TAK-659 suppressed splenomegaly and tumor devel-
opment in a LMP2A/Myc mouse model in nanomolar
concentrations. In addition, TAK-659 also blocked
metastasis of tumor cells into bone marrow. Interest-
ingly, TAK-659 killed tumor cells without damaging host
cells in spleen and tumors [85].
In a phase 1 first-in-human study of TAK-659
(NCT02000934), patients (pts) aged ≥18 years with
advanced solid tumors or lymphoma received oral TAK-
659 daily (QD, 60–120 mg) [86]. At the data cutoff on
June 15, 2015, 24 pts had been enrolled (14 solid tumor
pts; 10 lymphoma pts) at four dose levels of TAK-659
(60, 80, 100, 120 mg). Among the 10 lymphoma pts, 7
had DLBCL (5 GCB and 2 ABC subtypes) and 3 had
follicular lymphoma (FL). Among all the pts, the most
common AEs were fatigue, elevated AST, anemia, and
diarrhea. Eight patients (33%) had grade ≥3 drug-related
AEs. Of 7 response-evaluable DLBCL pts, 3 achieved
PR. Therefore, TAK-659 at dose 60–100 mg QD appears
to be acceptable for further studies.
In the updated report of this phase I first-in-human
study, 54 adult patients with advanced solid tumors/
lymphoma received oral TAK-659 QD at doses of 60, 80,
100, and 120 mg during dose escalation (n = 35) or
100 mg during dose expansion (n = 19) [87]. There were
five dose-limiting toxicities (DLTs): increased lipase
levels, generalized edema, mucositis, and increased AST.
MTD (maximal tolerated dose) was 100 mg daily. In this
updated report, 24 DLBCL pts were evaluable for
responses. Among these 24 pts, 11 (46%) achieved an
objective response; (7 (29%) CR, 4 PR); all 3 response-
evaluable FL pts achieved PR. No solid tumor patients
achieved an objective response.
A phase Ib/II study of TAK-659 is underway in pts
with relapsed or refractory acute myelogenous leukemia
(R/R AML) [88]. During the phase Ib dose escalation
study, adult pts with R/R AML received oral TAK-659
daily at doses of 60, 100, 120, and 160 mg. The pharma-
codynamic effect of TAK-659 was assessed using flow
cytometry by measuring the phosphorylation of riboso-
mal protein S6 (pS6) in peripheral AML blasts. DLT has
not been observed in the latest update. The median age
of the patients was 67 years (range 25–86), and 38% had
received ≥4 prior lines of therapy. TEAEs were seen in 12
(92%) pts overall; the most common AEs were elevated
AST (31%), ALT (23%), and amylase levels (23%). For PD
studies, pS6 was detected at baseline and reduced after
dosing in four patients (2 FLT-3-ITD; 2 FLT-3-WT). In-
hibition of FLT-3-ITD phosphorylation and early activity
with decreases in peripheral myeloblasts was observed.
The unique mechanism of action with dual inhibition of
Syk and FLT-3 appears to warrant further studies in R/R
AML patients with FLT-3 mutations.
Conclusion
Syk inhibitors are a new group of small molecule inhibi-
tors targeting BCR-mediated signaling pathways. The
second generation compound, entospletinib, showed
promising results in clinical trials against B-cell
malignancies, mainly CLL. There is an unmet need in
hematological malignancies for the new non-
chemotherapy drugs. Multidrug regimens in combin-
ation with other small molecule inhibitors and new
antibodies may have the potential of overcoming or
delaying the development of drug resistance [89–95].
The off-target effects of the small molecule inhibitors
are a limiting factor. Caution should be exerted espe-
cially in testing drug combinations [60].
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